Venous thromboembolism (VTE) is frequently encountered across various specialties. The management of VTE has become more nuanced, requiring consideration of several factors when deciding on the choice and duration of anticoagulation. This evidence-based review article summarises the current practice and evidence behind anticoagulation in VTE, incorporating national and international guidelines. Factors influencing decision-making around the choice and duration of anticoagulation, along with special circumstances such as cancer and antiphospholipid syndrome, are discussed. The clinical utility of thrombophilia screening is also addressed.
Keywords: Venous thromboembolism; anticoagulation; antiphospholipid syndrome; bleeding risk; cancer; direct oral anticoagulants; hepatic impairment; low molecular weight heparin; obesity; provoked; renal impairment; thrombophilia screening; unprovoked; warfarin.